While the U.S. gave Huawei a 90-day reprieve, allowing American businesses to keep selling specific products to the Chinese firm, it also added more affiliates of the...Technologyread more
United States Steel Corp will temporarily lay off hundreds of workers at its Great Lakes facility in Michigan in coming weeks, according to a filing the steelmaker made with...US Marketsread more
Home Depot shares, which are valued at $228.8 billion, are up more than 21% this year.Retailread more
The attacks come after state and local ransomware attacks in New York, Louisiana, Maryland and Florida resulted in the loss of significant sums.Technologyread more
U.K. Prime Minister Boris Johnson told the EU that a Brexit deal can still be approved by U.K. lawmakers if Brussels agrees to scrapping the contentious Irish "backstop."read more
Baidu posted better-than-expected earnings for the June quarter, swinging back to profit and managing to stabilize its core ad business.Technologyread more
Several big Pimco funds controlled by Ivascyn have reportedly been trimming their bond market positions in the U.K. and Europe.World Marketsread more
While Hong Kong leader Carrie Lam painted a bleak picture of the city's economy, she expressed hope that dialogue with protesters could provide "a way out."China Politicsread more
China's pursuit of the Middle East may spur growth in the Islamic finance sector.World Economyread more
Twitter and Facebook have suspended accounts believed to be tied to a state-backed disinformation campaign originating from inside China.Technologyread more
U.S. President Donald Trump and his former White House communications director Anthony Scaramucci have had a public falling out recently.Politicsread more
Some patients advocates and physicians have shown a lot of excitement for Opdivo's results, said Bristol-Myers Squibb CEO Giovanni Caforio.
Bristol-Myers' stock was up 3.33 percent to $66.76 during midday trading hours on Monday, after a sharp drop on Friday following the announcement of the trial results of Opdivo.
The results showed that Opdivo, which is used to treat lung cancer, wasn't effective for all levels of the condition.
"We are very focused on ensuring that our patients have access to our medicines," said Caforio during his first interview as CEO with CNBC. "They prolong survival. Just think about four years ago. There was really no hope for patients with melanoma."
"It really positions Opdivo as a foundational drug in lung cancer, melanoma, and the data is really exciting. We've shown that in some patients with non-squamous lung cancer, which is the most common form of the disease, Opdivo doubles survival. That's unprecedented data."
Caforio added that the company will continue to investigate the role of biomarkers. A biomarker is defined as "any substance, structure or process that can be measured in the body or its products and influence or predict the incidence of outcome or disease" by a venture of the World Health Organization.
Caforio also said that the company is entering a period of sustained growth.
"Business development is really very important to our strategy," Caforio said. "It will continue to be. We actually have a really integrated approach to innovation with internal R&D complemented by business development."
Caforio said that when looking at biotech pricing, it was important to take into account the very rapid progress.
"We look at strategic fit, the strength of the science, and obviously it must make sense financially," said Caforio.
CORRECTION: Bristol-Myers Squibb CEO Giovanni Caforio says patients with melanoma faced much worse odds even four years ago. The timeline in his quote was misstated in an earlier version of this article.